CYTK
Cytokinetics, Incorporated
Price Chart
Latest Quote
$78.78
+0.67 (+0.86%)
Current Price
| Previous Close | $78.11 |
| Open | $79.50 |
| Day High | $80.15 |
| Day Low | $77.14 |
| Volume | 3,082,308 |
Stock Information
| Shares Outstanding | 135.77M |
| Total Debt | $1.44B |
| Cash Equivalents | $818.55M |
| Revenue | $105.81M |
| Net Income | $-829.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.70B |
| EPS (TTM) | $-6.86 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.43B |
| Sales | $105.81M |
| Income | $-829.61M |
| Book/sh | $-6.65 |
| Cash/sh | $6.03 |
| Employees | 673 |
Financial Ratios
| Quick Ratio | 4.14 |
| Current Ratio | 4.21 |
Returns & Margins
| ROA | -31.54% |
| Gross Margin | -290.73% |
| Operating Margin | -948.69% |
Ownership
| Insider Ownership | 0.70% |
| Institutional Ownership | 118.79% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -16.57 |
| P/S | 101.08 |
| P/B | -11.84 |
Analyst Data
| Recommendation | buy |
| Target Price | $104.70 |
Technical Indicators
| SMA20 | $73.37 |
| SMA50 | $70.93 |
| SMA200 | $63.72 |
| RSI | 53.94 |
| ATR | 3.3457 |
| Shares Float | 123.87M |
| Short Float | 17.65% |
| Short Ratio | 4.40 |
| Volatility | 0.43 |
| Rel Volume | 1.84 |
Performance History
| Week | +13.73% |
| Month | +3.05% |
| Quarter | +25.15% |
| 6 Months | +27.02% |
| YTD | +27.62% |
| Year | +142.10% |
| 3 Years | +116.79% |
| 5 Years | +274.43% |
| 10 Years | +781.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $78.78 | 3,547,500 |
| 2026-06-17 | $78.11 | 3,340,400 |
| 2026-06-16 | $75.21 | 3,974,000 |
| 2026-06-15 | $71.38 | 1,012,300 |
| 2026-06-12 | $70.15 | 1,292,900 |
| 2026-06-11 | $69.27 | 1,443,300 |
| 2026-06-10 | $67.07 | 1,404,900 |
| 2026-06-09 | $68.45 | 2,492,700 |
| 2026-06-08 | $67.90 | 2,382,300 |
| 2026-06-05 | $71.48 | 1,614,100 |
| 2026-06-04 | $72.29 | 1,312,400 |
| 2026-06-03 | $70.71 | 1,595,100 |
| 2026-06-02 | $70.91 | 1,488,000 |
| 2026-06-01 | $73.68 | 1,659,900 |
| 2026-05-29 | $76.76 | 1,844,600 |
| 2026-05-28 | $76.81 | 1,972,000 |
| 2026-05-27 | $77.15 | 1,621,800 |
| 2026-05-26 | $76.29 | 1,652,100 |
| 2026-05-22 | $76.94 | 1,111,300 |
| 2026-05-21 | $78.06 | 1,775,300 |
| 2026-05-20 | $78.77 | 2,379,500 |
| 2026-05-19 | $76.45 | 2,399,100 |
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
đ° Latest News
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
Zacks âĸ 2026-06-17T14:54:00Z
Edgewise Bounds Between Double-Digit Losses And Gain â What's Going On?
Investor's Business Daily âĸ 2026-06-16T20:06:20Z
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment
Insider Monkey âĸ 2026-06-13T19:34:47Z
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)
Simply Wall St. âĸ 2026-06-08T10:07:38Z
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:11Z
Citi Calls Cytokinetics, Incorporated (CYTK) a âTop Pickâ Among Small-to-Mid Cap Biotech Stocks
Insider Monkey âĸ 2026-05-28T10:59:41Z
A Look At Cytokinetics (CYTK) Valuation After A Strong MultiâYear Share Price Performance
Simply Wall St. âĸ 2026-05-25T21:15:31Z
Citi Names 2 Biotech Stocks âTop Picksâ for 2026
TipRanks âĸ 2026-05-24T17:58:00Z
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
MarketBeat âĸ 2026-05-22T20:04:11Z
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-19T13:34:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $416,026,000 | $339,408,000 | $330,123,000 | $240,813,000 |
| Cost Of Revenue | $416,026,000 | $339,408,000 | $330,123,000 | $240,813,000 |
| Total Revenue | $88,039,000 | $18,474,000 | $7,530,000 | $94,588,000 |
| Operating Revenue | $88,039,000 | $18,474,000 | $7,530,000 | $94,588,000 |
| Expenses | ||||
| Interest Expense | $103,868,000 | $86,512,000 | $57,668,000 | $51,156,000 |
| Total Expenses | $700,297,000 | $554,722,000 | $503,735,000 | $418,790,000 |
| Other Income Expense | $-117,249,000 | $-18,300,000 | - | $-24,939,000 |
| Other Non Operating Income Expenses | $-200,000 | $-19,600,000 | - | - |
| Net Non Operating Interest Income Expense | $-55,448,000 | $-34,978,000 | $-30,039,000 | $-39,814,000 |
| Interest Expense Non Operating | $103,868,000 | $86,512,000 | $57,668,000 | $51,156,000 |
| Operating Expense | $700,297,000 | $554,722,000 | $503,735,000 | $418,790,000 |
| General And Administrative Expense | $284,271,000 | $215,314,000 | $173,612,000 | $177,977,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Net Interest Income | $-55,448,000 | $-34,978,000 | $-30,039,000 | $-39,814,000 |
| Interest Income | $48,420,000 | $51,534,000 | $27,629,000 | $11,342,000 |
| Normalized Income | $-667,906,000 | $-590,826,000 | $-526,244,000 | $-364,016,000 |
| Net Income From Continuing And Discontinued Operation | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Total Operating Income As Reported | $-612,258,000 | $-536,248,000 | $-496,205,000 | $-324,202,000 |
| Net Income Common Stockholders | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Net Income | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Net Income Including Noncontrolling Interests | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Net Income Continuous Operations | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Pretax Income | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Special Income Charges | $-121,249,000 | $0 | $0 | $-24,939,000 |
| Interest Income Non Operating | $48,420,000 | $51,534,000 | $27,629,000 | $11,342,000 |
| Operating Income | $-612,258,000 | $-536,248,000 | $-496,205,000 | $-324,202,000 |
| Gross Profit | $-327,987,000 | $-320,934,000 | $-322,593,000 | $-146,225,000 |
| Per Share | ||||
| Diluted EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 |
| Basic EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-553,913,000 | $-494,783,000 | $-456,684,000 | $-307,046,000 |
| Total Unusual Items | $-117,049,000 | $1,300,000 | $0 | $-24,939,000 |
| Total Unusual Items Excluding Goodwill | $-117,049,000 | $1,300,000 | $0 | $-24,939,000 |
| Reconciled Depreciation | $10,125,000 | $9,531,000 | $11,892,000 | $5,814,000 |
| EBITDA (Bullshit earnings) | $-670,962,000 | $-493,483,000 | $-456,684,000 | $-331,985,000 |
| EBIT | $-681,087,000 | $-503,014,000 | $-468,576,000 | $-337,799,000 |
| Diluted Average Shares | $120,103,000 | $111,979,000 | $96,524,000 | $89,825,000 |
| Basic Average Shares | $120,103,000 | $111,979,000 | $96,524,000 | $89,825,000 |
| Diluted NI Availto Com Stockholders | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Other Special Charges | $121,249,000 | - | - | $24,939,000 |
| Gain On Sale Of Security | $4,200,000 | $1,300,000 | - | - |
| Research And Development | $416,026,000 | $339,408,000 | $330,123,000 | $240,813,000 |
| Selling General And Administration | $284,271,000 | $215,314,000 | $173,612,000 | $177,977,000 |
| Other Gand A | $284,271,000 | $215,314,000 | $173,612,000 | $177,977,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-659,625,000 | $-135,372,000 | $-386,323,000 | $-107,900,000 |
| Total Assets | $1,424,537,000 | $1,401,673,000 | $824,316,000 | $1,014,775,000 |
| Total Non Current Assets | $507,562,000 | $293,733,000 | $196,265,000 | $219,589,000 |
| Other Non Current Assets | $17,341,000 | $7,705,000 | $7,996,000 | $9,691,000 |
| Investmentin Financial Assets | $335,048,000 | $145,055,000 | $40,534,000 | $46,708,000 |
| Current Assets | $916,975,000 | $1,107,940,000 | $628,051,000 | $795,186,000 |
| Other Current Assets | $16,990,000 | $15,276,000 | $11,944,000 | $12,462,000 |
| Receivables | $17,764,000 | $16,650,000 | $1,283,000 | $147,000 |
| Accounts Receivable | $17,764,000 | $16,650,000 | $1,283,000 | $147,000 |
| Cash Cash Equivalents And Short Term Investments | $882,221,000 | $1,076,014,000 | $614,824,000 | $782,577,000 |
| Cash And Cash Equivalents | $122,518,000 | $94,857,000 | $113,024,000 | $65,582,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,034,644,000 | $562,260,000 | $504,429,000 | $544,994,000 |
| Total Debt | $1,284,243,000 | $788,677,000 | $755,771,000 | $750,300,000 |
| Long Term Debt And Capital Lease Obligation | $1,223,951,000 | $758,179,000 | $727,800,000 | $736,513,000 |
| Long Term Debt | $1,115,981,000 | $645,597,000 | $607,373,000 | $609,618,000 |
| Current Debt And Capital Lease Obligation | $60,292,000 | $30,498,000 | $27,971,000 | $13,787,000 |
| Current Debt | $41,181,000 | $11,520,000 | $10,080,000 | $958,000 |
| Other Current Borrowings | $41,181,000 | $11,520,000 | $10,080,000 | $958,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,084,162,000 | $1,537,045,000 | $1,210,639,000 | $1,122,675,000 |
| Total Non Current Liabilities Net Minority Interest | $1,881,710,000 | $1,357,371,000 | $1,107,961,000 | $1,038,058,000 |
| Other Non Current Liabilities | $657,759,000 | $599,192,000 | $380,161,000 | $301,545,000 |
| Current Liabilities | $202,452,000 | $179,674,000 | $102,678,000 | $84,617,000 |
| Other Current Liabilities | $34,933,000 | $21,114,000 | $10,559,000 | $1,123,000 |
| Current Deferred Liabilities | $1,612,000 | $52,370,000 | $0 | - |
| Payables And Accrued Expenses | $60,465,000 | $40,560,000 | $34,893,000 | $47,940,000 |
| Payables | $22,337,000 | $20,369,000 | $21,507,000 | $25,611,000 |
| Accounts Payable | $22,337,000 | $20,369,000 | $21,507,000 | $25,611,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-659,625,000 | $-135,372,000 | $-386,323,000 | $-107,900,000 |
| Total Equity Gross Minority Interest | $-659,625,000 | $-135,372,000 | $-386,323,000 | $-107,900,000 |
| Stockholders Equity | $-659,625,000 | $-135,372,000 | $-386,323,000 | $-107,900,000 |
| Gains Losses Not Affecting Retained Earnings | $630,000 | $2,398,000 | $-10,000 | $-3,590,000 |
| Other Equity Adjustments | $630,000 | $2,398,000 | $-10,000 | $-3,590,000 |
| Retained Earnings | $-3,486,719,000 | $-2,701,764,000 | $-2,112,238,000 | $-1,585,994,000 |
| Other | ||||
| Ordinary Shares Number | $122,943,172 | $118,209,139 | $101,637,922 | $94,833,975 |
| Share Issued | $122,943,172 | $118,209,139 | $101,637,922 | $94,833,975 |
| Tangible Book Value | $-659,625,000 | $-135,372,000 | $-386,323,000 | $-107,900,000 |
| Invested Capital | $497,537,000 | $521,745,000 | $231,130,000 | $502,676,000 |
| Working Capital | $714,523,000 | $928,266,000 | $525,373,000 | $710,569,000 |
| Capital Lease Obligations | $127,081,000 | $131,560,000 | $138,318,000 | $139,724,000 |
| Total Capitalization | $456,356,000 | $510,225,000 | $221,050,000 | $501,718,000 |
| Additional Paid In Capital | $2,826,341,000 | $2,563,876,000 | $1,725,823,000 | $1,481,590,000 |
| Capital Stock | $123,000 | $118,000 | $102,000 | $94,000 |
| Common Stock | $123,000 | $118,000 | $102,000 | $94,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $107,970,000 | $112,582,000 | $120,427,000 | $126,895,000 |
| Current Deferred Revenue | $1,612,000 | $52,370,000 | $0 | - |
| Current Capital Lease Obligation | $19,111,000 | $18,978,000 | $17,891,000 | $12,829,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $45,150,000 | $35,132,000 | $29,255,000 | $21,767,000 |
| Current Accrued Expenses | $38,128,000 | $20,191,000 | $13,386,000 | $22,329,000 |
| Investments And Advances | $335,048,000 | $145,055,000 | $40,534,000 | $46,708,000 |
| Available For Sale Securities | $335,048,000 | $145,055,000 | $40,534,000 | $46,708,000 |
| Net PPE | $155,173,000 | $140,973,000 | $147,735,000 | $163,190,000 |
| Accumulated Depreciation | $-47,301,000 | $-37,177,000 | $-28,348,000 | $-17,094,000 |
| Gross PPE | $202,474,000 | $178,150,000 | $176,083,000 | $180,284,000 |
| Leases | $80,203,000 | $66,874,000 | $66,874,000 | $65,912,000 |
| Construction In Progress | $10,351,000 | $4,067,000 | $220,000 | $741,000 |
| Other Properties | $99,938,000 | $97,787,000 | $99,665,000 | $103,675,000 |
| Machinery Furniture Equipment | $11,982,000 | $9,422,000 | $9,324,000 | $9,956,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $759,703,000 | $981,157,000 | $501,800,000 | $716,995,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-534,816,000 | $-399,796,000 | $-415,749,000 | $-310,851,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-510,009,000 | $-395,890,000 | $-414,333,000 | $-299,516,000 |
| Cash Flow From Continuing Operating Activities | $-510,009,000 | $-395,890,000 | $-414,333,000 | $-299,516,000 |
| Operating Gains Losses | $-4,225,000 | $-1,274,000 | $35,000 | $2,800,000 |
| Investing Activities | ||||
| Capital Expenditure | $-24,807,000 | $-3,906,000 | $-1,416,000 | $-11,335,000 |
| Investing Cash Flow | $16,666,000 | $-553,097,000 | $239,253,000 | $-262,134,000 |
| Cash Flow From Continuing Investing Activities | $16,666,000 | $-553,097,000 | $239,253,000 | $-262,134,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $706,844,000 | $164,233,000 | $0 |
| Financing Cash Flow | $524,458,000 | $930,611,000 | $221,317,000 | $516,166,000 |
| Cash Flow From Continuing Financing Activities | $524,458,000 | $930,611,000 | $221,317,000 | $516,166,000 |
| Net Other Financing Charges | $172,532,000 | $180,369,000 | $39,483,000 | $163,962,000 |
| Net Common Stock Issuance | $0 | $706,844,000 | $164,233,000 | $0 |
| Common Stock Issuance | $0 | $706,844,000 | $164,233,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-413,513,000 | $-9,618,000 | $-858,000 | $-188,925,000 |
| Issuance Of Debt | $729,460,000 | $0 | $0 | $523,586,000 |
| Interest Paid Supplemental Data | $22,914,000 | $25,970,000 | $10,295,000 | $15,165,000 |
| End Cash Position | $125,632,000 | $95,232,000 | $113,399,000 | $67,182,000 |
| Beginning Cash Position | $95,232,000 | $113,399,000 | $67,182,000 | $112,666,000 |
| Effect Of Exchange Rate Changes | $-715,000 | $209,000 | $-20,000 | $0 |
| Changes In Cash | $31,115,000 | $-18,376,000 | $46,237,000 | $-45,484,000 |
| Proceeds From Stock Option Exercised | $35,979,000 | $53,016,000 | $18,459,000 | $17,543,000 |
| Net Issuance Payments Of Debt | $315,947,000 | $-9,618,000 | $-858,000 | $334,661,000 |
| Net Long Term Debt Issuance | $315,947,000 | $-9,618,000 | $-858,000 | $334,661,000 |
| Long Term Debt Payments | $-413,513,000 | $-9,618,000 | $-858,000 | $-188,925,000 |
| Long Term Debt Issuance | $729,460,000 | $0 | $0 | $523,586,000 |
| Net Investment Purchase And Sale | $41,473,000 | $-549,191,000 | $240,669,000 | $-250,799,000 |
| Sale Of Investment | $1,109,646,000 | $744,225,000 | $875,880,000 | $604,594,000 |
| Purchase Of Investment | $-1,068,173,000 | $-1,293,416,000 | $-635,211,000 | $-855,393,000 |
| Net PPE Purchase And Sale | $-24,807,000 | $-3,906,000 | $-1,416,000 | $-11,335,000 |
| Purchase Of PPE | $-24,807,000 | $-3,906,000 | $-1,416,000 | $-11,335,000 |
| Change In Working Capital | $-35,628,000 | $35,664,000 | $3,089,000 | $-24,704,000 |
| Change In Other Working Capital | $-50,758,000 | $52,370,000 | - | $-87,000,000 |
| Change In Other Current Liabilities | $-17,089,000 | $-8,600,000 | $-10,991,000 | $-2,330,000 |
| Change In Payables And Accrued Expense | $36,266,000 | $9,699,000 | $13,620,000 | $15,368,000 |
| Change In Accrued Expense | $33,603,000 | $14,182,000 | $17,103,000 | $10,844,000 |
| Change In Payable | $2,663,000 | $-4,483,000 | $-3,483,000 | $4,524,000 |
| Change In Account Payable | $2,663,000 | $-4,483,000 | $-3,483,000 | $4,524,000 |
| Change In Prepaid Assets | $-2,933,000 | $-2,438,000 | $1,596,000 | $-7,414,000 |
| Change In Receivables | $-1,114,000 | $-15,367,000 | $-1,136,000 | $56,672,000 |
| Changes In Account Receivables | $-1,114,000 | $-15,367,000 | $-1,136,000 | $56,672,000 |
| Other Non Cash Items | $192,388,000 | $51,875,000 | $24,830,000 | $57,676,000 |
| Stock Based Compensation | $112,286,000 | $97,840,000 | $72,065,000 | $47,853,000 |
| Depreciation Amortization Depletion | $10,125,000 | $9,531,000 | $11,892,000 | $5,814,000 |
| Depreciation And Amortization | $10,125,000 | $9,531,000 | $11,892,000 | $5,814,000 |
| Depreciation | $10,125,000 | $9,531,000 | $11,892,000 | $5,814,000 |
| Gain Loss On Investment Securities | $-4,225,000 | $-1,319,000 | $35,000 | $107,000 |
| Gain Loss On Sale Of PPE | $0 | $45,000 | $0 | $0 |
| Net Income From Continuing Operations | $-784,955,000 | $-589,526,000 | $-526,244,000 | $-388,955,000 |
| Asset Impairment Charge | - | - | $0 | $0 |
Fetched: 2026-06-17